US4267171A
Expired / Lapsed
US
⏱️ 0.0 years remaining
C-5 Substituted cytosine nucleosides
Assignee: University of California, San Diego
•
Filing: 1979-07-02
•
Granted: 1981-05-12
•
Expires: 1999-07-02
Abstract
Abstract C-5 Substituted cytosine nucleosides wherein the C-5 substituent is substituted alkyl, alkenyl or substituted alkenyl; and the pharmaceutically acceptable acid addition salts thereof, are useful as antiviral agents. A novel process for the preparation of the subject compounds is also disclosed.
Inventors
- 👤 Donald E. Bergstrom
- 👤 Jerry L. Ruth
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 06:07
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
54 words
A compound of the formula ##STR9## wherein R o is β-D-ribofuranosyl, β-D-2-deoxyribofuranosyl or β-D-arabinofuranosyl and R is selected from the group consisting of ##STR10## wherein R 1 is hydrogen; R 3 is hydrogen or methyl; R 4 is C 1-4 lower alkyl; R 6 is hydrogen; and the pharmaceutically acceptable acid addition salts thereof.
Claim 2
Dependent Claim
54 words
A compound of the formula ##STR9## wherein R o is β-D-ribofuranosyl, β-D-2-deoxyribofuranosyl or β-D-arabinofuranosyl and R is selected from the group consisting of ##STR10## wherein R 1 is hydrogen; R 3 is hydrogen or methyl; R 4 is C 1-4 lower alkyl; R 6 is hydrogen; and the pharmaceutically acceptable acid addition salts thereof.
Claim 3
Dependent Claim
11 words
A compound according to claim 1 wherein R o is β-D-2-deoxyribofuranosyl.
Claim 4
Dependent Claim
11 words
A compound according to claim 2 wherein R 3 is hydrogen.
Claim 5
Dependent Claim
8 words
The compound of claim 2 which is 5-(ethenyl)-2'-deoxycytidine.
Claim 6
Dependent Claim
10 words
A compound according to claim 2, wherein R is allyl.
Claim 7
Dependent Claim
10 words
A compound according to claim 2, wherein R is 1-methoxyethyl.
Claim 8
Independent Claim
37 words
A method of treating herpes simplex virus 1 in a host mammal afflicted with such infection which comprises administering to said host an effective amount of a compound according to claims 2, 3, 4, 5 or 5.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-05-11 | 1984-11-10 | 1985-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-05-11 | 1988-11-10 | 1989-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-05-11 | 1992-11-10 | 1993-05-12 | $7700.00 | Window Closed / Lapsed |